Exchange of human material for diagnostics development and production

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032367

Enrollment

Registered

2023-09-01

Start date

2023-09-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Goodpasture's syndrome Anti-PLA2R / Primary membranous nephropathy ANCA-associated vasculitis Type 1 diabetes Lambert-Eaton Myasthenic Syndrome (LEMS) Multiple Sclerosis (MS) CNS vasculitis Autoimmune Hematitis Primary biliary cholangitis

Interventions

Group 1: Patients of the University Medical Center Rostock who receive apharesis due to an autoimmune disease The material usually discarded after plasmapheresis or immunoadsorption treatment can be

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - signed consent form - Apharesis treatment due to autoimmune disease

Exclusion criteria

Exclusion criteria: Patient is not capable of giving consent

Design outcomes

Primary

Measure	Time frame
Development, verification and provision of in vitro diagnostic test methods	—

Countries

Germany

Contacts

Public ContactSteffen Mitzner

Universitätsmedizin Rostock

steffen.mitzner@med.uni-rostock.de+493814947730

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026